Axsome Therapeutics, Inc. (AXSM)
| Market Cap | 2.65B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -102.90M |
| Shares Out | 37.21M |
| EPS (ttm) | -2.77 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 3 |
| Last Price | $70.18 |
| Previous Close | $69.76 |
| Change ($) | 0.42 |
| Change (%) | 0.60% |
| Day's Open | 69.37 |
| Day's Range | 68.70 - 71.49 |
| Day's Volume | 247,314 |
| 52-Week Range | 35.44 - 109.53 |
Axsome (AXSM) reports wider-than-expected loss in the fourth quarter of 2020. The company files an NDA for AXS-05 to treat major depressive disorder.
NEW YORK, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) ...
This company presents much more attractive prospects than the cryptocurrency.
From vaccines to diagnostics, the opportunities in biotechnology are rich for those who do their homework.
While it's already made some people rich, Axsome Therapeutics is just getting started.
Take a look at a few trending biotech stocks and decide if this is something you want to invest in.
Investors need to pay close attention to Axsome Therapeutics (AXSM) stock based on the movements in the options market lately.
Axsome (AXSM) posts favorable data from the long-term phase III study evaluating AXS-07 for acute treatment of migraine. The company also begins a second phase III study on AXS-05 for AD agita...
ACCORD is the second pivotal trial of AXS-05 in Alzheimer's disease agitation
Over 21,000 migraine attacks treated with AXS-07
The second half of 2020 has been pretty dull in terms of AXSM trading relative to the first half. Several positive readouts in H2'20 provided only a modest boost but set the stage for a H1'21 ...
68 % reduction in MADRS Suicidality Item score by Week 1, and 82% reduction by Week 4
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?
R apid and substantial i mprovement in depressive symptoms achieved by 44 % of patients at 2 weeks, 67 % at 6 weeks (MADRS response) , and sustained with long-term treatment
R apid and substantial improvement in depressive symptoms achieved by 40% of patients at 2 weeks, 73% at 6 weeks (MADRS response) , and sustained over 12 months
Axsome (AXSM) earnings meet estimates in the third quarter. The company stretches the timeline for the NDA filing for AXS-05 and AXS-07.
Axsome Therapeutics, Inc. (AXSM) CEO Herriot Tabuteau on Q3 2020 Results - Earnings Call Transcript
NEW YORK & PLEASANTON, Calif.--(BUSINESS WIRE)-- #digitalengagement--Axsome and Veeva announced a strategic partnership to augment the build of Axsome's Digital-Centric Commercialization (DCC™...
NEW YORK, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) ...
Axsome to host conference call and webcast on Thursday, November 5, 2020 at 8:00 AM Eastern Time
Axsome has an excellent pipeline of late stage CNS candidates. The total market opportunity of all 4 assets is nearly $8bn.
When it comes to extreme wealth creation, few endeavors can compare to being an owner of a small-cap stock that grows large. The post Small-Cap Stocks Have Led Every Bull Market for Decades ap...
The Recent Sell-Off In Axsome Creates A Good Opportunity
An analyst doesn't think very highly of Axsome's prospects.
Non-dilutive committed capital extends cash runway into at least 2024
S ignificantly faster time to pain relief as compared to rizatriptan (p
Axsome (AXSM) accelerates the development plan for AXS-12 to treat narcolepsy after a Breakthrough Therapy meeting with the FDA authorities. Stock dips.
Axsome Reports Positive Data, And Other News: The Good, Bad And Ugly Of Biopharma
Single Phase 3 trial to be conducted to support an NDA filing of AXS-12 in the treatment of narcolepsy; trial initiation anticipated 1Q 2021
Data from MOMENTUM Phase 3 trial to be presented at the 2020 AAN Science Highlights Platform
There was not one single catalyst causing yesterday's rally; however, there was some excitement in the market from vaccine progress, and indicators of economic recovery. For investors looking ...
Rapid, durable, and statistically significant improvement demonstrated in patient-reported depressive symptoms, as measured by the QIDS-SR-16 total score compared to placebo (p=0.001)
NEW YORK, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CN...
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?
A day after the worst single-day drop in three months, equity markets are wavering between plunging into a deeper sell-off or recouping their losses. For investors who anticipate that this wav...
NEW YORK, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CN...
Previously completed positive, pivotal ADVANCE-1 trial sufficient with single additional Phase 3 efficacy trial for NDA in Alzheimer’s disease agitation
NEW YORK, Aug. 28, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS...
Axsome (AXSM) concludes a favorable pre-NDA meeting with the FDA for AXS-07, which is developed as an acute treatment of migraine. The company is on course to file the NDA in Q4.
NDA submission on track for 4Q 2020
Axsome (AXSM) incurs a narrower loss in the second quarter of 2020. The company remains on track to submit the NDA for AXS-05 and AXS-07.
The company announced that it is on track to submit two of its pipeline candidates to the FDA by year-end.
Axsome Therapeutics, Inc. (AXSM) CEO Herriot Tabuteau on Q2 2020 Results - Earnings Call Transcript
Two NDA submissions, for AXS-05 in MDD and for AXS-07 in migraine, on track for 4Q 2020
Axsome to host conference call and webcast on Monday, August 10, 2020 at 8:00 AM Eastern Time
The Secondary Impact Of COVID-19 Pandemic Leads To Bigger Market Potential For Axsome Therapeutics
Axsome (AXSM) concludes a favorable pre-NDA meeting with the FDA officials for AXS-05 to treat major depressive disorder. The company is on course to file the NDA in Q4.
NDA submission on track for 4Q 2020
About AXSM
Axsome Therapeutics, a clinical stage biopharmaceutical company, engages in developing novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05, which is in the phase III clinical trial for the treatment resistant depression and depressive disorders; and phase II/III clinical trials in agitation associated with Alzheimer's disease, as well as completed phase II clinical trial for the treatment of smoking cessation. The company is also developing AXS-07, which is in phase III clinical ... [Read more...]
| Industry Biotechnology | IPO Date Nov 19, 2015 |
| CEO Herriot Tabuteau | Employees 53 |
| Stock Exchange NASDAQ | Ticker Symbol AXSM |
Analyst Forecasts
According to 14 analysts, the average rating for AXSM stock is "Strong Buy." The 12-month stock price forecast is 143.85, which is an increase of 104.97% from the latest price.